메뉴 건너뛰기




Volumn 2017, Issue , 2017, Pages

The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGESTERONE RELEASING PEPTIDE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIGEN CYFRA21.1; CARRIER PROTEIN; CYTOKERATIN 19; NSE1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-GASTRIN-RELEASING PEPTIDE (31-98); RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN;

EID: 85019970209     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/2013989     Document Type: Article
Times cited : (62)

References (39)
  • 2
    • 0345872083 scopus 로고    scopus 로고
    • Multidisciplinary management of lung cancer
    • A. Spira and D. S. Ettinger, "Multidisciplinary management of lung cancer, "The New England Journal ofMedicine, vol. 350, no. 4, pp. 379-392, 2004.
    • (2004) The New England Journal OfMedicine , vol.350 , Issue.4 , pp. 379-392
    • Spira, A.1    Ettinger, D.S.2
  • 3
    • 2942547465 scopus 로고    scopus 로고
    • Small cell lung cancer: State of the art and future perspectives
    • R. Stupp, C. Monnerat, A. T. Turrisi, M. C. Perry, andS. Leyvraz, "Small cell lung cancer: state of the art and future perspectives, " Lung Cancer, vol. 45, no. 1, pp. 105-117, 2004.
    • (2004) Lung Cancer , vol.45 , Issue.1 , pp. 105-117
    • Stupp, R.1    Monnerat, C.2    Turrisi, A.T.3    Perry, M.C.4    Leyvraz, S.5
  • 4
    • 0035742095 scopus 로고    scopus 로고
    • Current standards of care in small-cell and nonsmall-cell lung cancer
    • J. H. Schiller, "Current standards of care in small-cell and nonsmall-cell lung cancer, " Oncology, vol. 61, no. 1, pp. 3-13, 2001.
    • (2001) Oncology , vol.61 , Issue.1 , pp. 3-13
    • Schiller, J.H.1
  • 5
    • 0036328377 scopus 로고    scopus 로고
    • Practice guidelines for tumor marker use in the clinic
    • C. Sturgeon, "Practice guidelines for tumor marker use in the clinic, " Clinical Chemistry, vol. 48, pp. 1151-1159, 2002.
    • (2002) Clinical Chemistry , vol.48 , pp. 1151-1159
    • Sturgeon, C.1
  • 6
    • 0028330525 scopus 로고
    • Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma
    • Y. Miyake, T. Kodama, and K. Yamaguchi, "Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma, " Cancer Research, vol. 54, pp. 2136-2140, 1994.
    • (1994) Cancer Research , vol.54 , pp. 2136-2140
    • Miyake, Y.1    Kodama, T.2    Yamaguchi, K.3
  • 7
    • 0033728154 scopus 로고    scopus 로고
    • Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treatedwith platinum-based chemotherapy
    • E. Quoix, A. Purohit, M. Faller-Beau, L. Moreau, J. P. Oster, and G. Pauli, "Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treatedwith platinum-based chemotherapy, " LungCancer, vol. 30, no. 2, pp. 127-134, 2000.
    • (2000) LungCancer , vol.30 , Issue.2 , pp. 127-134
    • Quoix, E.1    Purohit, A.2    Faller-Beau, M.3    Moreau, L.4    Oster, J.P.5    Pauli, G.6
  • 8
    • 0034159916 scopus 로고    scopus 로고
    • Significance of serumprogastrin-releasing peptide as a predictor of relapse of small cell lung cancer: Comparative evaluation with neuron-specific enolase and carcinoembryonic antigen
    • S. Niho, Y. Nishiwaki, K. Goto et al., "Significance of serumprogastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen, " Lung Cancer, vol. 27, no. 3, pp. 159-167, 2000.
    • (2000) Lung Cancer , vol.27 , Issue.3 , pp. 159-167
    • Niho, S.1    Nishiwaki, Y.2    Goto, K.3
  • 9
    • 0035103446 scopus 로고    scopus 로고
    • Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC)
    • T. Shibayama, H. Ueoka, K. Nishii et al., "Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC), " Lung Cancer, vol. 32, no. 1, pp. 61-69, 2001.
    • (2001) Lung Cancer , vol.32 , Issue.1 , pp. 61-69
    • Shibayama, T.1    Ueoka, H.2    Nishii, K.3
  • 10
    • 0030016693 scopus 로고    scopus 로고
    • Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres
    • L. G. M. Jørgensen, K. Østerlind, J. Genollá et al., "Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres, " British Journal of Cancer, vol. 74, no. 3, pp. 463-467, 1996.
    • (1996) British Journal of Cancer , vol.74 , Issue.3 , pp. 463-467
    • Jørgensen, L.G.M.1    Østerlind, K.2    Genollá, J.3
  • 11
    • 9344265211 scopus 로고    scopus 로고
    • Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer
    • M. Díez, A. Torres, M. L. Maestro et al., "Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer, " British Journal of Cancer, vol. 73, no. 10, pp. 1248-1254, 1996.
    • (1996) British Journal of Cancer , vol.73 , Issue.10 , pp. 1248-1254
    • Díez, M.1    Torres, A.2    Maestro, M.L.3
  • 12
    • 0026937685 scopus 로고
    • Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer
    • J. Niklinski, M. Furman, J. Laudanski, and M. Kozlowski, "Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer, " European Journal of Cancer Prevention, vol. 1, no. 6, pp. 401-406, 1992.
    • (1992) European Journal of Cancer Prevention , vol.1 , Issue.6 , pp. 401-406
    • Niklinski, J.1    Furman, M.2    Laudanski, J.3    Kozlowski, M.4
  • 13
    • 0033428435 scopus 로고    scopus 로고
    • Tumor markers CEA, NSE, SCC, TPA and CYFRA 21. 1 in resectable non-small cell lung cancer
    • P. Foa, M. Fornier, and R. Miceli, "Tumor markers CEA, NSE, SCC, TPA and CYFRA 21. 1 in resectable non-small cell lung cancer, " Anticancer Research, vol. 19, pp. 3613-3618, 1999.
    • (1999) Anticancer Research , vol.19 , pp. 3613-3618
    • Foa, P.1    Fornier, M.2    Miceli, R.3
  • 14
    • 0024935769 scopus 로고
    • Preliminary study on CA 125 and CA 19. 9 in primary lung cancer. Relationship with histological subtype of lung carcinoma
    • R. Molina, P. Santabarbara, X. Filella, P. Mengual, and A. M. Ballesta, "Preliminary study on CA 125 and CA 19. 9 in primary lung cancer. Relationship with histological subtype of lung carcinoma, "The International Journal of BiologicalMarkers, vol. 4, pp. 215-220, 1990.
    • (1990) The International Journal of BiologicalMarkers , vol.4 , pp. 215-220
    • Molina, R.1    Santabarbara, P.2    Filella, X.3    Mengual, P.4    Ballesta, A.M.5
  • 15
    • 0028200489 scopus 로고
    • CYFRA 21. 1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels
    • R. Molina, C. Agusti, M. Mae et al., "CYFRA 21. 1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels, "The International Journal of Biological Markers, vol. 9, pp. 96-101, 1994.
    • (1994) The International Journal of Biological Markers , vol.9 , pp. 96-101
    • Molina, R.1    Agusti, C.2    Mae, M.3
  • 16
    • 0027293239 scopus 로고
    • The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer
    • W. Eberth, B. Leichtweis, B. Schapöhler, and T. H. Muley, "The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer, " Tumor Diagnostik und Therapie, vol. 14, pp. 91-99, 1993.
    • (1993) Tumor Diagnostik und Therapie , vol.14 , pp. 91-99
    • Eberth, W.1    Leichtweis, B.2    Schapöhler, B.3    Muley, T.H.4
  • 17
    • 0029557611 scopus 로고
    • CYFRA 21. 1 determination in patients with non-small cell lung cancer: Clinical utility for the detection of recurrence
    • J. Niklinski, M. Furman, M. Rappellino et al., "CYFRA 21. 1 determination in patients with non-small cell lung cancer: clinical utility for the detection of recurrence, " The Journal of Cardiovascular Surgery, vol. 36, pp. 501-504, 1995.
    • (1995) The Journal of Cardiovascular Surgery , vol.36 , pp. 501-504
    • Niklinski, J.1    Furman, M.2    Rappellino, M.3
  • 18
    • 0027279541 scopus 로고
    • CYFRA 21-1: A new marker in lung cancer
    • P. Stieber, U. Hasholzner, H. Bodenmüller et al., "CYFRA 21-1: a new marker in lung cancer, " Cancer, vol. 72, no. 3, pp. 707-713, 1993.
    • (1993) Cancer , vol.72 , Issue.3 , pp. 707-713
    • Stieber, P.1    Hasholzner, U.2    Bodenmüller, H.3
  • 19
    • 0027530418 scopus 로고
    • Serumfragment of cytokeratin subunit 19measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer
    • J.-L. Pujol, J. Grenier, J.-P. Daurfes, A. Daver, H. Pujol, and F.-B. Michel, "Serumfragment of cytokeratin subunit 19measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer, " Cancer Research, vol. 53, pp. 61-66, 1993.
    • (1993) Cancer Research , vol.53 , pp. 61-66
    • Pujol, J.-L.1    Grenier, J.2    Daurfes, J.-P.3    Daver, A.4    Pujol, H.5    Michel, F.-B.6
  • 20
    • 0029073304 scopus 로고
    • Cyfra 21-1 as a biologic marker of non-small cell lung cancer: Evaluation of sensitivity, specificity, and prognostic role
    • B. Wieskopf, C. Demangeat, A. Purohit et al., "Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role, " Chest, vol. 108, no. 1, pp. 163-169, 1995.
    • (1995) Chest , vol.108 , Issue.1 , pp. 163-169
    • Wieskopf, B.1    Demangeat, C.2    Purohit, A.3
  • 21
    • 0345059332 scopus 로고    scopus 로고
    • Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with nonsmall cell lung cancer as an aid in histological diagnosis and prognosis: Comparison with the main clinical and pathological prognostic factors
    • R. Molina, X. Filella, J. M. Augé et al., "Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with nonsmall cell lung cancer as an aid in histological diagnosis and prognosis: comparison with the main clinical and pathological prognostic factors, " Tumor Biology, vol. 24, no. 4, pp. 209-218, 2003.
    • (2003) Tumor Biology , vol.24 , Issue.4 , pp. 209-218
    • Molina, R.1    Filella, X.2    Augé, J.M.3
  • 24
    • 0030960735 scopus 로고    scopus 로고
    • Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma
    • T. Yoshimasu, S. Miyoshi, S. Maebeya et al., "Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma, " Cancer, vol. 79, no. 8, pp. 1533-1540, 1997.
    • (1997) Cancer , vol.79 , Issue.8 , pp. 1533-1540
    • Yoshimasu, T.1    Miyoshi, S.2    Maebeya, S.3
  • 27
    • 15744362912 scopus 로고    scopus 로고
    • The 2004World Health Organization classification of lung tumors
    • M. B. Beasley, E. Brambilla, and W. D. Travis, "The 2004World Health Organization classification of lung tumors, " Seminars in Roentgenology, vol. 40, no. 2, pp. 90-97, 2005.
    • (2005) Seminars in Roentgenology , vol.40 , Issue.2 , pp. 90-97
    • Beasley, M.B.1    Brambilla, E.2    Travis, W.D.3
  • 28
    • 66449111135 scopus 로고    scopus 로고
    • Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: Correlation with histology
    • R. Molina, J. M. Augé, X. Bosch et al., "Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology, " Tumor Biology, vol. 30, no. 3, pp. 121-129, 2009.
    • (2009) Tumor Biology , vol.30 , Issue.3 , pp. 121-129
    • Molina, R.1    Augé, J.M.2    Bosch, X.3
  • 29
    • 0031924565 scopus 로고    scopus 로고
    • Tumor markers in response monitoring and prognosis of non-small cell lung cancer: Preliminary report
    • N. Viñolas, R. Molina, M. C. Galán et al., "Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report, " Anticancer Research, vol. 18, pp. 631-634, 1998.
    • (1998) Anticancer Research , vol.18 , pp. 631-634
    • Viñolas, N.1    Molina, R.2    Galán, M.C.3
  • 30
    • 0028000030 scopus 로고
    • Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases
    • R. Molina, C. Agusti, X. Filella et al., "Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases, " Tumor Biology, vol. 15, no. 6, pp. 318-325, 1994.
    • (1994) Tumor Biology , vol.15 , Issue.6 , pp. 318-325
    • Molina, R.1    Agusti, C.2    Filella, X.3
  • 31
    • 0037314212 scopus 로고    scopus 로고
    • Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer
    • J.-L. Pujol, X. Quantin, W. Jacot, J.-M. Boher, J. Grenier, and P.-J. Lamy, "Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer, " Lung Cancer, vol. 39, no. 2, pp. 131-138, 2003.
    • (2003) Lung Cancer , vol.39 , Issue.2 , pp. 131-138
    • Pujol, J.-L.1    Quantin, X.2    Jacot, W.3    Boher, J.-M.4    Grenier, J.5    Lamy, P.-J.6
  • 32
    • 34250734403 scopus 로고    scopus 로고
    • Value of tumour and inflammatory markers in lung cancer
    • G. M. Oremek, H. Sauer-Eppel, and T. H. Bruzdziak, "Value of tumour and inflammatory markers in lung cancer, " Anticancer Research, vol. 27, pp. 1911-1915, 2007.
    • (2007) Anticancer Research , vol.27 , pp. 1911-1915
    • Oremek, G.M.1    Sauer-Eppel, H.2    Bruzdziak, T.H.3
  • 35
    • 0031041970 scopus 로고    scopus 로고
    • Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer
    • T. Okusaka, K. Eguchi, and T. Kasai, "Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer, " Clinical Cancer Research, vol. 3, pp. 123-127, 1997.
    • (1997) Clinical Cancer Research , vol.3 , pp. 123-127
    • Okusaka, T.1    Eguchi, K.2    Kasai, T.3
  • 36
    • 3042552039 scopus 로고    scopus 로고
    • Pro-gastrin-releasing peptide in patients with benign and malignant diseases
    • R. Molina, J. M. Auge, J. Alicarte, X. Filella, N. Viñolas, and A. M. Ballesta, "Pro-gastrin-releasing peptide in patients with benign and malignant diseases, " Tumor Biology, vol. 25, no. 1-2, pp. 56-61, 2004.
    • (2004) Tumor Biology , vol.25 , Issue.1-2 , pp. 56-61
    • Molina, R.1    Auge, J.M.2    Alicarte, J.3    Filella, X.4    Viñolas, N.5    Ballesta, A.M.6
  • 37
    • 79955630045 scopus 로고    scopus 로고
    • Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer
    • H.-R. Kim, I.-J. Oh, M.-G. Shin et al., "Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer, " Journal of Korean Medical Science, vol. 26, no. 5, pp. 625-630, 2011.
    • (2011) Journal of Korean Medical Science , vol.26 , Issue.5 , pp. 625-630
    • Kim, H.-R.1    Oh, I.-J.2    Shin, M.-G.3
  • 38
    • 84940100919 scopus 로고    scopus 로고
    • The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification
    • W. D. Travis, E. Brambilla, A. G. Nicholson et al., "The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification, " Journal ofThoracic Oncology, vol. 10, no. 9, pp. 1243-1260, 2015.
    • (2015) Journal OfThoracic Oncology , vol.10 , Issue.9 , pp. 1243-1260
    • Travis, W.D.1    Brambilla, E.2    Nicholson, A.G.3
  • 39
    • 85017325012 scopus 로고    scopus 로고
    • NCCN guidelines 2017, https://www.nccn. org/store/login/login. aspxreturnURL=https://www.nccn. org/professionals/physician- gls/pdf/sclc. pdf.
    • (2017) NCCN Guidelines


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.